Document is current
Any future updates will be listed below
-
Authors
Bazell, Carol M.
Alston, Maggie N.
Ganti, Latha G.
Chang, Raymond C.
Wilsey, H. Andrew
Leary, Stephanie A.
Fopalan, Winston C.
Baugh, Christopher W.
-
Funding
Funding for this research was provided by:
AstraZeneca Pharmaceuticals LP
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 16 June 2025
First Online: 22 July 2025
Declarations
:
: Carol Bazell, Maggie Alston, Stephanie Leary, and Winston Fopalan are employees of Milliman Inc. and received consulting fees from AstraZeneca. Latha Ganti is a consultant for AstraZeneca. Raymond Chang and H Andrew Wilsey are employees of AstraZeneca Pharmaceuticals LP and own stock in AstraZeneca. Christopher Baugh is a paid speaker for Roche Diagnostics; participated in Roche Advisory Boards; is an advisor to Lucia Health Guidelines, Quai, and Vera Health; serves on advisory boards for Pfizer, Salix Pharmaceuticals, and AstraZeneca; and has received research funding support from Abbott Laboratories, Roche Diagnostics, and Sanofi. AstraZeneca Pharmaceuticals LP produces and markets ANDEXXA (coagulation factor Xa [recombinant], inactivated-zhzo), a drug used for the reversal of anticoagulation in patients treated with apixaban and rivaroxaban. The authors report no other conflicts of interest in this work.
: This manuscript is based on previously collected non-identifiable healthcare administrative claims data and does not contain any new studies with human participants or animals performed by any of the authors. All uses of data in this manuscript fall under Milliman Inc.’s existing data use agreements for the data sources.
